MA32642B1 - Amides utiles en therapie - Google Patents
Amides utiles en therapieInfo
- Publication number
- MA32642B1 MA32642B1 MA33710A MA33710A MA32642B1 MA 32642 B1 MA32642 B1 MA 32642B1 MA 33710 A MA33710 A MA 33710A MA 33710 A MA33710 A MA 33710A MA 32642 B1 MA32642 B1 MA 32642B1
- Authority
- MA
- Morocco
- Prior art keywords
- optionally substituted
- substituents
- alkyl
- independently selected
- oxo
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
La présente invention concerne un composé de formule (i), ou un sel ou un solvate pharmaceutiquement acceptables de celui-ci, (i) dans laquelle, r1 et r2 représentent chacun indépendamment h, un halogène, cf3, un alkyle en c1 à c3 ou un alcoxy en c1 à c3; r3 représente un alkyle en c1 à c6, un cycloalkyle en c3 à c6, un phényle (éventuellement substitués par un ou plusieurs substituants chacun indépendamment choisi parmi ra) ou het (éventuellement substitué par un ou plusieurs substituants chacun indépendamment choisi parmi oh, un oxo, ou un alkyle en c1 à c4); r4 représente h ou un alkyle en c1 à c3; r5 représente un alkyle en c1 à c6 (éventuellement substitué par un ou plusieurs substituants chacun indépendamment choisi parmi rb), un cycloalkyle en c3 à c6 (éventuellement substitué par un ou plusieurs substituants chacun indépendamment choisi parmi un oxo ou oh), ou het2 (éventuellement substitué par un ou plusieurs substituants chacun indépendamment choisi parmi rd); un atome d'oxygène ou 1 atome de soufre, ou (c) 1 atome d'oxygène ou 1 atome de soufre, (éventuellement substitué par un ou plusieurs substituants chacun indépendamment choisis parmi oh, un oxo ou un alkyle en c1 à c4); et r6 représente un alkyle en c1 à c3 (éventuellement substitué par un ou plusieurs substituants chacun indépendamment choisi parmi rf), un cycloalkyle en c3 à c5 (éventuellement substitué par un ou plusieurs halogènes), cn ou un halogène; où rf représente un halogène ou un phényle. L'invention concerne également des compositions, des procédés de préparation, et des utilisations de celles-ci, par exemple dans le traitement de l'endométriose ou de fibromes utérins.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9790208P | 2008-09-18 | 2008-09-18 | |
| PCT/IB2009/054038 WO2010032200A1 (fr) | 2008-09-18 | 2009-09-16 | Composés amides utiles en thérapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32642B1 true MA32642B1 (fr) | 2011-09-01 |
Family
ID=41269630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33710A MA32642B1 (fr) | 2008-09-18 | 2011-03-18 | Amides utiles en therapie |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8232269B2 (fr) |
| EP (1) | EP2350017A1 (fr) |
| JP (1) | JP2012502975A (fr) |
| KR (1) | KR20110044304A (fr) |
| CN (1) | CN102159548A (fr) |
| AP (1) | AP2011005611A0 (fr) |
| AU (1) | AU2009294290B2 (fr) |
| BR (1) | BRPI0918935A2 (fr) |
| CA (1) | CA2735931A1 (fr) |
| CL (1) | CL2011000570A1 (fr) |
| CO (1) | CO6351734A2 (fr) |
| DO (1) | DOP2011000083A (fr) |
| EA (1) | EA201100368A1 (fr) |
| EC (1) | ECSP11010901A (fr) |
| IL (1) | IL211479A0 (fr) |
| MA (1) | MA32642B1 (fr) |
| MX (1) | MX2011002899A (fr) |
| PE (1) | PE20110793A1 (fr) |
| WO (1) | WO2010032200A1 (fr) |
| ZA (1) | ZA201102690B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5964407B2 (ja) * | 2011-04-21 | 2016-08-03 | オリオン コーポレーション | アンドロゲン受容体調節カルボキシアミド |
| EP2734042B1 (fr) * | 2011-07-21 | 2017-02-01 | The Regents Of The University Of California | Ciblage de protéines gli dans un cancer humain par des petites molécules |
| US9416109B2 (en) | 2012-02-17 | 2016-08-16 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
| EP2700635A1 (fr) | 2012-08-20 | 2014-02-26 | Basf Se | Dérivés d'amides de 5-trifluorométhylpyrazole en tant qu'herbicides |
| WO2014116651A1 (fr) | 2013-01-23 | 2014-07-31 | The Regents Of The University Of California | Ciblage de protéines gli à l'aide de petites molécules dans un cancer humain |
| EA027879B1 (ru) | 2013-02-22 | 2017-09-29 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK) |
| WO2014143617A1 (fr) * | 2013-03-14 | 2014-09-18 | Teva Women's Health, Inc. | Tanaproget enrichi en deutérium et procédés de préparation associés |
| WO2016024185A1 (fr) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Dérivés de pyrrolo[2,3-d]pyrimidine utiles pour inhiber la janus kinase |
| US20190321363A1 (en) * | 2016-06-20 | 2019-10-24 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
| CN108623446A (zh) * | 2017-03-24 | 2018-10-09 | 北京艾德旺科技发展有限公司 | 一种合成3，3-二氟环丁烷甲酸的方法 |
| EP3946606B1 (fr) | 2019-03-27 | 2025-01-01 | Insilico Medicine IP Limited | Inhibiteurs de jak bicycliques et leurs utilisations |
| EP4053124A1 (fr) * | 2019-10-28 | 2022-09-07 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Composé d'acide oxocarboxylique hétérocyclique à cinq chaînons et son utilisation médicale |
| WO2023217203A2 (fr) * | 2022-05-12 | 2023-11-16 | 西北农林科技大学 | Procédé de préparation d'un composé de diphényl pyrazole |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2604218A1 (fr) * | 2005-04-20 | 2006-10-26 | Pfizer Limited | Derives de pyrazole tenant lieu d'antagonistes du recepteur de la progesterone |
| CA2623327A1 (fr) * | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | Compose heterocyclique azote et composition pharmaceutique le contenant |
-
2009
- 2009-09-16 KR KR1020117006161A patent/KR20110044304A/ko not_active Ceased
- 2009-09-16 JP JP2011527444A patent/JP2012502975A/ja not_active Withdrawn
- 2009-09-16 EA EA201100368A patent/EA201100368A1/ru unknown
- 2009-09-16 CN CN2009801364939A patent/CN102159548A/zh active Pending
- 2009-09-16 CA CA2735931A patent/CA2735931A1/fr not_active Abandoned
- 2009-09-16 MX MX2011002899A patent/MX2011002899A/es not_active Application Discontinuation
- 2009-09-16 PE PE2011000628A patent/PE20110793A1/es not_active Application Discontinuation
- 2009-09-16 AU AU2009294290A patent/AU2009294290B2/en not_active Expired - Fee Related
- 2009-09-16 BR BRPI0918935A patent/BRPI0918935A2/pt not_active IP Right Cessation
- 2009-09-16 EP EP09787204A patent/EP2350017A1/fr not_active Withdrawn
- 2009-09-16 AP AP2011005611A patent/AP2011005611A0/xx unknown
- 2009-09-16 WO PCT/IB2009/054038 patent/WO2010032200A1/fr not_active Ceased
- 2009-09-17 US US12/561,398 patent/US8232269B2/en not_active Expired - Fee Related
-
2011
- 2011-02-28 IL IL211479A patent/IL211479A0/en unknown
- 2011-03-17 DO DO2011000083A patent/DOP2011000083A/es unknown
- 2011-03-17 CL CL2011000570A patent/CL2011000570A1/es unknown
- 2011-03-17 EC EC2011010901A patent/ECSP11010901A/es unknown
- 2011-03-18 MA MA33710A patent/MA32642B1/fr unknown
- 2011-03-25 CO CO11036952A patent/CO6351734A2/es not_active Application Discontinuation
- 2011-04-11 ZA ZA2011/02690A patent/ZA201102690B/en unknown
-
2012
- 2012-06-18 US US13/525,893 patent/US20120316150A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201100368A1 (ru) | 2011-12-30 |
| US20100249091A1 (en) | 2010-09-30 |
| CL2011000570A1 (es) | 2011-06-17 |
| PE20110793A1 (es) | 2011-10-31 |
| ZA201102690B (en) | 2011-12-28 |
| AU2009294290A1 (en) | 2010-03-25 |
| US20120316150A1 (en) | 2012-12-13 |
| AP2011005611A0 (en) | 2011-04-30 |
| EP2350017A1 (fr) | 2011-08-03 |
| CO6351734A2 (es) | 2011-12-20 |
| KR20110044304A (ko) | 2011-04-28 |
| AU2009294290B2 (en) | 2012-08-30 |
| IL211479A0 (en) | 2011-05-31 |
| CN102159548A (zh) | 2011-08-17 |
| US8232269B2 (en) | 2012-07-31 |
| DOP2011000083A (es) | 2011-03-31 |
| BRPI0918935A2 (pt) | 2015-12-01 |
| MX2011002899A (es) | 2011-04-11 |
| JP2012502975A (ja) | 2012-02-02 |
| ECSP11010901A (es) | 2011-04-29 |
| WO2010032200A1 (fr) | 2010-03-25 |
| CA2735931A1 (fr) | 2010-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200601830A1 (ru) | Ортозамещённые арильные или гетероарильные амидные соединения | |
| MX2009008465A (es) | Nuevas 2-aminooxazolinas como ligandos de taar1. | |
| MA29323B1 (fr) | Composes de l'acide pyridylacetique | |
| ATE556058T1 (de) | 1-(2h)-isochinolonderivat | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| WO2005080384A3 (fr) | Dérivé du benzimidazole et ses utilisations | |
| MY150269A (en) | Novel phenylpyrrole derivative | |
| MA30724B1 (fr) | Procede de preparation d'acide 4-amino-butyrique substitue par biaryle ou de derives de celui-ci et leur utilisation pour produire des inhibiteurs de nep. | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| MA33851B1 (fr) | Compose heterocyclique contenant de l'azote et fongicide agricole | |
| ATE538099T1 (de) | 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden | |
| CA2642211A1 (fr) | Composes de 2,4-pyrimidinediamine pour le traitement ou la prevention de maladies autoimmunes | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR071792A1 (es) | Antagonistas nitrogenados del receptor de glucagon, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de la diabetes tipo ii y afecciones relacionadas. | |
| MA28973B1 (fr) | Compose heterocyclique fusionne | |
| NZ610312A (en) | 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors | |
| MA32088B1 (fr) | Dérivés bicycliques de carboxamides azabicycliques, leur préparation et leur application en thérapeutique | |
| MA33581B1 (fr) | Composition pharmaceutique contenant un dérivé de quinoléine | |
| JP2010535722A5 (fr) | ||
| DE602005005167D1 (de) | 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor | |
| MA30397B1 (fr) | 2-(pyridine-2-yl)-pyrimidines utilisées comme fongicides | |
| BRPI0513777A (pt) | composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| EA201100368A1 (ru) | Амидные соединения, полезные в терапии | |
| FR2998298B1 (fr) | Synthese de sels d’imidazo[1,2-a]pyrazin-4-ium pour la synthese du 1,4,7-triazacyclononane (tacn) et de ses derives n- et/ou c-fonctionnalises |